Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28241167 | 0.85 | EPHX1 (0.52) | SLC6A4CYP2D6SIGMAR1TAAR1MAOA | |
| SCHEMBL6325819 | 0.84 | SLC6A4 (0.54) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL636097 | 0.80 | ALDH1A1 (0.49) | SLC6A4LTA4HCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL27838804 | 0.79 | SLC6A2 (0.47) | SLC6A4CYP2D6SIGMAR1TAAR1MAOA | |
| SCHEMBL637388 | 0.78 | SLC6A4 (0.50) | SLC6A4CYP1A2CYP2D6CYP2C19TAAR1 | |
| SCHEMBL635989 | 0.77 | SLC6A4 (0.56) | SLC6A4CYP1A2CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL2671508 | 0.77 | LTA4H (0.60) | LTA4HALDH1A1SIGMAR1MEN1KMT2A | |
| SCHEMBL6327948 | 0.77 | SLC6A4 (0.57) | SLC6A4CYP1A2CYP2D6CYP2C19LDHA | |
| SCHEMBL1153290 | 0.76 | KDM4E (0.69) | SLC6A4LTA4HCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL1153287 | 0.76 | KDM4E (0.69) | SLC6A4LTA4HCYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12129249-B2 | Method for producing optically active compound | DAY ONE BIOPHARMACEUTICALS, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| EP-4406609-A2 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | Day One Biopharmaceuticals, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| US-20210347769-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS, INC. | 2021-11-11 | — | — | US | disclosed |
| US-10988469-B2 | Method for producing optically active compound | DOT THERAPEUTICS-1, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200317659-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS, INC. | 2020-10-08 | — | — | US | disclosed |
| EP-3632441-A2 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | Millennium Pharmaceuticals, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| US-20180079741-A1 | PROCESS FOR PRODUCING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| US-9809569-B2 | Process for producing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-07 | — | — | US | disclosed |
| US-20170081305-A1 | PROCESS FOR PRODUCING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-23 | — | — | US | disclosed |
| CN-106458897-A | Process for producing heterocyclic compound | 武田药品工业株式会社 | 2017-02-22 | — | — | CN | disclosed |
| US-9238667-B2 | Rhodium catalyst and method for producing amine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-19 | — | — | US | disclosed |
| US-8981147-B2 | Diphosphine ligand and transition metal complex using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-17 | — | — | US | disclosed |
| US-20150051416-A1 | RHODIUM CATALYST AND METHOD FOR PRODUCING AMINE COMPOUND | SPERA PHARMA, INC. (JP) | 2015-02-19 | — | — | US | disclosed |
| EP-2832738-A1 | RHODIUM CATALYST AND METHOD FOR PRODUCING AMINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-02-04 | — | — | EP | disclosed |
| US-20140171655-A1 | DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-06-19 | — | — | US | disclosed |
| EP-1927596-B9 | DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME | TAKEDA PHARMACEUTICAL (JP) | 2013-05-15 | — | — | EP | disclosed |
| EP-1927596-B1 | DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME | TAKEDA PHARMACEUTICAL (JP) | 2012-08-01 | — | — | EP | disclosed |
| EP-2420507-A1 | Diphosphine ligand and transition metal complex using the same | Takeda Pharmaceutical Company Limited (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20090270635-A1 | Diphosphine Ligand and Transition Metal Complex Using the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-10-29 | — | — | US | disclosed |
| EP-1927596-A1 | DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2008-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081305-A1 | PROCESS FOR PRODUCING HETEROCYCLIC COMPOUND | DHPS, QDPR, DPYD | SLC6A4 2573/4885LTA4H 2030/4885CYP1A2 28/4885 |
| US-10988469-B2 | Method for producing optically active compound | DHPS, QDPR, SPR | SLC6A4 1615/4885LTA4H 1564/4885CYP1A2 1113/4885 |
| US-20180079741-A1 | PROCESS FOR PRODUCING HETEROCYCLIC COMPOUND | DHPS, QDPR, DPYD | SLC6A4 2573/4885LTA4H 2030/4885CYP1A2 28/4885 |
| US-20200317659-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DHPS, QDPR, SPR | SLC6A4 1615/4885LTA4H 1564/4885CYP1A2 1113/4885 |
| US-20150051416-A1 | RHODIUM CATALYST AND METHOD FOR PRODUCING AMINE COMPOUND | PRMT7, PRMT5, HNMT | SLC6A4 544/4885LTA4H 4083/4885CYP1A2 235/4885 |
| US-12129249-B2 | Method for producing optically active compound | DHPS, QDPR, SPR | SLC6A4 1615/4885LTA4H 1564/4885CYP1A2 1113/4885 |
| US-20090270635-A1 | Diphosphine Ligand and Transition Metal Complex Using the Same | MVD, C5, C1S | SLC6A4 3807/4885LTA4H 684/4885CYP1A2 45/4885 |
| US-20140171655-A1 | DIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX USING THE SAME | MVD, C5, C1S | SLC6A4 3807/4885LTA4H 684/4885CYP1A2 45/4885 |
| US-20210347769-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DHPS, QDPR, SPR | SLC6A4 1615/4885LTA4H 1564/4885CYP1A2 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.